Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


Gilead Sciences, Inc. 

333 Lakeside Drive

Foster City  California  94404  U.S.A.
Phone: 800-GILEAD-5 or 650-574-3000 Fax: 650-522-5800


Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

Key Contacts:
John C. Martin, PhD, Chairman and Chief Executive Officer
John F. Milligan, PhD, President and Chief Operating Officer
Norbert W. Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer
Kevin Young, Executive Vice President, Commercial Operations
Gregg Alton, Executive Vice President, Corporate and Medical Affairs
Kristen Metza, Senior Vice President, Human Resources
Robin Washington, Senior Vice President and Chief Financial Officer
Susan Hubbard, Vice President, Investor Relations
Amy Flood, Vice President, Public Affairs

 Key Statistics

Ownership: Public

Web Site: Gilead Sciences, Inc.
Employees: 4,000
Symbol: GILD


 Company News
Gilead Sciences, Inc. (GILD)’s Sovaldi® Demonstrates Efficacy And Safety Among Chronic Hepatitis C Patients With Advanced Liver Disease 4/11/2014 8:09:37 AM    More...
Doctors Welcome Hepatitis C Drug Rivals, Gilead Sciences, Inc. (GILD) Still Leads 4/11/2014 6:19:01 AM    More...
Gilead Sciences, Inc. (GILD) Announces Phase 2 Results For Two Investigational All-Oral Sofosbuvir-Based Regimens For The Treatment Of Chronic Hepatitis C 4/10/2014 9:23:46 AM    More...
Gilead Sciences, Inc. (GILD) Announces Results From Study Of Sovaldi® For Retreatment Of Chronic Hepatitis C In Patients Not Cured With Prior Antiviral Therapy 4/10/2014 9:12:31 AM    More...
Beware Gilead Sciences, Inc. (GILD), Merck & Co., Inc. (MRK)'s Hepatitis C Combo Pill Impresses In Phase 2 Trial 4/10/2014 6:05:24 AM    More...
Pharmacy Benefit Manager Express Scripts Inc. Enraged, Looks To Force Gilead Sciences, Inc. (GILD) To Cut Price Of Sovaldi 4/9/2014 6:00:25 AM    More...
Gilead Sciences, Inc. (GILD)'s Ledipasvir/Sofosbuvir Fixed-Dose Combo Hep C Tablet Wins FDA Priority Review 4/7/2014 6:37:42 AM    More...
The Rapacious Enrichment Of Gilead Sciences, Inc. (GILD)'s CEO 4/3/2014 7:39:29 AM    More...
Gilead Sciences, Inc. (GILD)'s Japanese Hepatitis C Trial Meets Goal 4/2/2014 5:02:41 PM    More...
European Medicines Agency Validates Gilead Sciences, Inc. (GILD)’s Marketing Application For Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet For Genotype 1 Chronic Hepatitis C Infection 3/28/2014 9:18:04 AM    More...